Skip to content
Evigrade
CriticalNon-steroidal antiandrogen×Prokinetic, 5-HT4 serotonin receptor agonist (withdrawn EU/US)

Updated · Methodology

Mechanism

The active R-enantiomer of bicalutamide inhibits CYP3A4. After 28 days of bicalutamide, the mean exposure (area under the concentration-time curve, AUC) of midazolam, which CYP3A4 metabolises, rose by up to 80% (bicalutamide summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). For drugs with a narrow therapeutic index such a rise may matter, so the Spanish bicalutamide SmPC contraindicates cisapride. With erythromycin, another CYP3A4 inhibitor, blood levels of cisapride rose, with a risk of QT prolongation and ventricular arrhythmias (erythromycin SmPC, AEMPS). Androgen deprivation itself can prolong the QT interval, although a causal link with bicalutamide has not been established (bicalutamide SmPC, AEMPS).

Symptoms

High cisapride levels can cause QT prolongation, ventricular tachycardia, ventricular fibrillation and torsade de pointes (erythromycin summary of product characteristics, SmPC, on its combination with cisapride, Spanish Agency of Medicines and Medical Devices, AEMPS). QT prolongation itself causes no symptoms and shows only on an electrocardiogram (ECG), while a ventricular arrhythmia causes sudden strong palpitations, dizziness or fainting and can lead to cardiac arrest. The bicalutamide SmPC lists QT prolongation among adverse reactions of unknown frequency. In people with risk factors for QT prolongation or taking QT-prolonging drugs, it names a potential risk of torsade de pointes (bicalutamide SmPC, AEMPS).

Management

The combination is contraindicated. The Spanish bicalutamide summaries of product characteristics (SmPCs), for the originator and the generics, at 50 mg and 150 mg, contraindicate bicalutamide with cisapride (bicalutamide SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). The US bicalutamide label does not name cisapride and only advises caution with all drugs that CYP3A4 metabolises (bicalutamide label, US Food and Drug Administration, FDA), so the stricter Spanish SmPC sets the level. Cisapride is not in the Spanish medicines register CIMA. If a person takes cisapride obtained in another country, do not give bicalutamide with it (bicalutamide SmPC, AEMPS). No document states how long to wait after stopping bicalutamide before starting cisapride. The half-life of the active form of bicalutamide is about one week (bicalutamide SmPC, AEMPS). If the regimen includes other QT-prolonging drugs or the person has risk factors for QT prolongation, weigh the benefit and risk, including the potential risk of torsade de pointes, before starting bicalutamide (bicalutamide SmPC, AEMPS). In people with heart disease taking bicalutamide 150 mg, the SmPC recommends periodic monitoring of cardiac function (bicalutamide SmPC, AEMPS).

Your whole list in one report

Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email

Add more drugs

Medicine list: everything you take in one place →

Sources

Other interactions with Cisapride